Oncimmune Holdings PLC Board Changes (7658H)
01 August 2023 - 4:00PM
UK Regulatory
TIDMONC
RNS Number : 7658H
Oncimmune Holdings PLC
01 August 2023
1 August 2023
Oncimmune Holdings plc
("Oncimmune" or the "Company")
Changes to the Board
Oncimmune Holdings plc (AIM: ONC.L), the leading autoantibody
profiling company to the pharmaceutical and biotechnology industry,
is pleased to announce that Martin Gouldstone has today started as
the Company's new Chief Executive Officer and joined the Board of
Directors.
With Martin as Chief Executive Officer, Ron Kirschner, who was
appointed as acting Chief Executive Officer in June, will be taking
up the role of Chief Operating Officer and has stepped down from
the Board. Ron remains Oncimmune's Company Secretary.
Regulatory disclosures in relation to Martin Gouldstone's
appointment, as required under Schedule 2(g) of the AIM Rules for
Companies, were contained in the Company's announcement on 12 July
2023 and have not changed as at the date of this announcement.
For further information:
Oncimmune Holdings plc
contact@oncimmune.co.uk
Singer Capital Markets (Nominated Adviser and Broker)
Phil Davies, Harry Gooden, George Tzimas, James Fischer
+44 (0)20 7496 3000
Zeus (Joint Broker)
Dominic King, Victoria Ayton, Dan Bate
+44 (0)20 3829 5000
+44 (0)20 3727 1000
About Oncimmune
Oncimmune is a specialist pharmaceutical services company,
primarily focused on the growing fields of immuno-oncology,
autoimmune disease and infectious diseases. Oncimmune has a
contract discovery and development service business whose
ImmunoINSIGHTS platform delivers actionable insights into therapies
to the Company ' s pharmaceutical and biotech partners.
Our understanding of the immune system enables us to harness its
sophisticated response to disease to detect cancer earlier and to
support the development of better therapies. The key to improving
cancer survival is early detection and better selection for
therapy. As a company, we are driven by our passion to improve
cancer survival and to give people extra time.
Oncimmune ' s ImmunoINSIGHTS platform enables life science
organisations to optimise drug development and delivery, leading to
more effectively targeted and safer treatments for patients.
Oncimmune ' s ImmunoINSIGHTS service business at its discovery
research centre in Dortmund, Germany. The ImmunoINSIGHTS business
development team are based in the US and Europe.
For more information, visit www.oncimmune.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
BOASDEFFFEDSEIW
(END) Dow Jones Newswires
August 01, 2023 02:00 ET (06:00 GMT)
Oncimmune (LSE:ONC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Oncimmune (LSE:ONC)
Historical Stock Chart
From Apr 2023 to Apr 2024